한글목차

오피오이드 사용 장애(OUD) 동향 및 예측

세계 오피오이드 사용 장애(OUD) 시장의 미래는 병원 약국 및 소매 약국 시장에 기회가 있는 유망한 시장으로 전망되고 있습니다. 세계 오피오이드 사용 장애(OUD) 시장은 2024년부터 2030년까지 10.3%의 연평균 복합 성장률(CAGR)로 성장을 지속하여 2030년까지 약 72억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 암, 심혈관 질환, 정형외과 질환과 같은 만성 질환의 유병률 증가와 부프레노르핀 패치가 효율적인 치료 옵션으로 인식되고 있다는 점입니다.

• Lucintel의 예측에 따르면, 약물 유형별로는 고령화 인구 증가와 오피오이드 남용의 유병률 증가로 인해 작용제가 예측 기간 동안 큰 비중을 차지할 것으로 보입니다.
• 유통 채널별로는 의료 인프라 구축을 위한 정부 지출 증가로 인해 병원 약국이 계속해서 큰 비중을 차지할 것으로 보입니다.
• 지역별로는 오피오이드 남용 치료제의 출시 및 승인 증가로 인해 북미가 예측 기간 동안 가장 규모가 큰 지역으로 남을 것으로 보입니다.

오피오이드 사용 장애(OUD) 시장의 전략적 성장 기회

오피오이드 사용 장애(OUD) 시장은 다양한 응용 분야에서 몇 가지 전략적 성장 기회를 제공합니다. 이러한 기회를 활용하면 치료 결과를 개선하고, 접근성을 확대하며, 진행 중인 오피오이드 위기에 효과적으로 대응할 수 있습니다.

• MAT 프로그램 확대: 치료 접근성이 낮은 지역으로 약수처리 지원 프로그램을 확대하는 것은 큰 성장 잠재력을 가지고 있습니다. 부프레노르핀과 메타돈과 같은 MAT의 선택권을 늘리면 OUD로 고통받는 사람들의 효과적인 치료 접근성을 향상시킬 수 있습니다.
• 디지털 건강 솔루션 통합: 원격 의료 및 모바일 앱을 포함한 디지털 건강 솔루션의 통합은 성장 기회를 제공합니다. 이러한 도구는 치료 제공, 환자 참여 및 모니터링을 강화하고 시장 확대의 새로운 길을 열어줍니다.
• 새로운 치료법 개발: 신약 제제나 병용요법 등 새로운 치료법 연구개발에 대한 투자는 성장의 기회를 제공합니다. 미충족 수요를 충족시키는 혁신적인 치료법은 시장 점유율을 확보하고 치료 옵션을 개선할 수 있습니다.
• 유해물질 저감 프로그램 확대: 주사바늘 교환 서비스, 모니터링 소비 사이트 등 유해물질 저감 프로그램의 확대는 성장 기회가 있습니다. 이러한 프로그램은 오피오이드 사용의 영향을 줄이고 치료와 회복을 위한 경로를 제공할 수 있습니다.
• 통합 치료 모델 강화: OUD 치료와 정신 건강 및 사회적 지원 서비스를 결합한 통합 치료 모델의 개발 및 실행은 성장 잠재력을 가지고 있습니다. 이러한 모델은 환자의 결과를 개선하고 OUD 환자의 다면적인 요구를 충족시킬 수 있습니다.

OUD 시장의 전략적 성장 기회에는 MAT 프로그램 확대, 디지털 헬스 솔루션 통합, 새로운 치료법 개발, 피해 감소 이니셔티브 확대, 통합적 치료 모델 강화 등이 포함됩니다. 이러한 기회는 시장의 진화하는 니즈에 부합하고 치료 및 회복 결과를 크게 개선할 수 있는 기회입니다.

오피오이드 사용 장애(OUD) 시장 성장 촉진요인 및 과제

오피오이드 사용 장애(OUD) 시장은 기술 발전, 경제적 요인, 규제 변화 등 다양한 촉진요인과 과제에 의해 크게 영향을 받습니다. 촉진요인으로는 치료 옵션의 혁신, 인식 개선, 정책 개혁, 경제적 인센티브, 치료 접근성 향상 등이 있습니다. 반면, 규제적 장애물, 경제적 장벽, 치료 순응도 및 접근성 문제 등이 도전요인으로 작용합니다. 이러한 요인을 이해하는 것은 OUD 시장의 복잡성을 극복하고 효과적인 치료와 관리를 위한 전략을 강화하고자 하는 이해관계자들에게 매우 중요합니다.

오피오이드 사용 장애(OUD) 시장을 주도하는 요인은 다음과 같습니다.

1. 기술 발전: 디지털 건강 도구 및 첨단 약물 처방과 같은 치료 기술 혁신이 OUD 시장의 성장을 가속하고 있습니다. 디지털 플랫폼은 원격 모니터링, 원격 의료, 개인화된 치료 계획을 용이하게 하여 환자 참여와 결과를 개선합니다. 서방형 옵션을 포함한 새로운 약물 제제는 치료 효과와 편의성을 향상시켜 시장 수요 증가에 기여하고 있습니다.

2. 인식과 교육 향상: 오피오이드 위기와 OUD에 대한 인식이 높아짐에 따라 효과적인 치료에 대한 수요가 증가하고 있습니다. 교육 캠페인과 공중보건 활동은 오피오이드 중독에 대한 이해를 높이고, 편견을 없애고, 치료를 받도록 장려하고 있습니다. 이러한 인식 증가는 더 많은 사람들이 OUD 관리 솔루션의 필요성을 인식하게 되면서 시장 성장의 원동력이 되고 있습니다.

3. 정책 및 규제 개혁: 정책 및 정책 변화에 따라 OUD 치료에 대한 접근성이 향상되고 있습니다. 약물보조요법(MAT) 보험 적용 확대 및 지원법 등 정부의 이니셔티브으로 치료의 장벽이 낮아지고 있습니다. 이러한 개혁은 의료 서비스 제공업체들이 다양한 치료 옵션을 제공하도록 장려하여 환자의 전반적인 접근성을 향상시키고 있습니다.

4. 경제적 인센티브 및 자금 지원: 정부 및 민간 자금 지원이 증가하여 OUD 치료 프로그램 및 연구를 지원하고 있으며, MAT에 대한 보조금 및 중독 치료 시설에 대한 보조금과 같은 경제적 인센티브는 의료 서비스 제공업체가 종합적인 치료를 제공하는 데 도움이 되고 있습니다. 이러한 재정적 지원은 치료의 가용성과 혁신성을 높이고 시장 성장을 가속하고 있습니다.

5. 치료 접근성 확대: 특히 의료 서비스가 부족한 지역과 지방에서 OUD 치료에 대한 접근성을 확대하려는 노력이 시장 성장을 견인하고 있습니다. 치료 센터의 수를 늘리고, 이동식 치료 유닛을 제공하고, 1차 의료 서비스에 치료를 통합하려는 노력은 치료 접근성을 향상시키고 있습니다. 이러한 노력은 더 많은 사람들이 OUD 관리에 필요한 치료를 받을 수 있도록 돕고 있습니다.

오피오이드 사용 장애(OUD) 시장의 과제는 다음과 같습니다.

1. 규제적 장애물: 복잡한 규제 요건을 극복하고 새로운 치료법을 승인받는 것은 어려운 일입니다. 지역별로 상이한 규제는 혁신적인 치료제 시장 진입을 지연시키고 보급에 장애가 될 수 있습니다. 또한, 엄격한 가이드라인을 준수하는 것은 제조업체의 비용을 증가시키고 치료제의 사용을 제한할 수 있습니다.

2. 경제적 장벽: 약물 및 치료 프로그램을 포함한 OUD 치료와 관련된 높은 비용은 큰 장벽이 될 수 있습니다. 경제적 제약은 환자가 필요한 치료에 대한 접근성을 제한하고 치료 순응도에 영향을 미칠 수 있습니다. 불충분한 보험 적용과 본인 부담금은 이러한 문제를 더욱 악화시켜 전체 시장 성장에 영향을 미칠 수 있습니다.

3. 치료 순응도 및 접근성 문제: 일관된 치료 순응도를 보장하고 접근성 문제를 해결하는 것은 큰 과제입니다. 환자들은 부작용, 낙인, 지원 부족으로 인해 치료 순응도에 어려움을 겪을 수 있습니다. 특히 외딴 지역에서는 치료 센터의 접근성이 제한되어 있어 접근성을 저해하고 OUD 관리 노력의 효과에 영향을 미칠 수 있습니다.

오피오이드 사용 장애 시장은 다양한 시장 성장 촉진요인과 과제가 복잡하게 얽혀 형성되고 있습니다. 기술 발전, 인식 개선, 정책 개혁, 경제적 인센티브, 접근성 확대는 치료의 효과와 접근성을 높이는 주요 촉진요인입니다. 그러나 규제적 장애물, 경제적 장벽, 치료 순응도 및 접근성 문제는 큰 도전이 되고 있습니다. 이러한 요인들을 해결하는 것은 시장 전략을 최적화하고 오피오이드 사용 장애 환자들의 치료 결과를 개선하기 위해 매우 중요하며, OUD 치료의 전망을 발전시키고자 하는 이해관계자들은 이러한 역학을 이해하고 이를 극복하는 것이 필수적입니다.

목차

제1장 주요 요약

제2장 세계의 오피오이드 사용 장애(OUD) 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2018년-2030년)

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 오피오이드 사용 장애(OUD) 시장 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 오피오이드 사용 장애(OUD) 시장 : 약제 유형별
  • 작용제
  • 길항제
• 세계의 오피오이드 사용 장애(OUD) 시장 : 연령층별
  • 19-39세
  • 40-59세
  • 60세 이상
• 세계의 오피오이드 사용 장애(OUD) 시장 : 투여 경로별
  • 경구
  • 정맥내
  • 설하
• 세계의 오피오이드 사용 장애(OUD) 시장 : 유통 채널별
  • 병원 약국
  • 소매 약국

제4장 지역별 시장 동향과 예측 분석(2018년-2030년)

• 세계의 오피오이드 사용 장애(OUD) 시장 : 지역별
• 북미의 오피오이드 사용 장애(OUD) 시장
• 유럽의 오피오이드 사용 장애(OUD) 시장
• 아시아태평양의 오피오이드 사용 장애(OUD) 시장
• 기타 지역의 오피오이드 사용 장애(OUD) 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 오피오이드 사용 장애(OUD) 시장 성장 기회 : 약제 유형별
  • 세계의 오피오이드 사용 장애(OUD) 시장 성장 기회 : 연령층별
  • 세계의 오피오이드 사용 장애(OUD) 시장 성장 기회 : 투여 경로별
  • 세계의 오피오이드 사용 장애(OUD) 시장 성장 기회 : 유통 채널별
  • 세계의 오피오이드 사용 장애(OUD) 시장 성장 기회 : 지역별
• 세계 오피오이드 사용 장애(OUD) 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 오피오이드 사용 장애(OUD) 시장 생산능력 확대
  • 세계 오피오이드 사용 장애(OUD) 시장의 인수합병(M&A) 및 합작투자
  • 인증 및 라이선싱

제7장 주요 기업 개요

• Hikma Pharmaceuticals
• Indivior
• Titan Pharmaceuticals
• Reckitt Benckiser Pharmaceuticals
• Camurus
• BioDelivery Sciences International
• Sandoz

영문목차

Opioid Use Disorder (OUD) Trends and Forecast

The future of the global opioid use disorder (OUD) market looks promising with opportunities in the hospital pharmacy and retail pharmacy markets. The global opioid use disorder (OUD) market is expected to reach an estimated $7.2 billion by 2030 with a CAGR of 10.3% from 2024 to 2030. The major drivers for this market are the growing prevalence of chronic diseases, such as cancer, cardiovascular diseases, and orthopedic diseases, and the increasing recognition of buprenorphine patches as an efficient treatment option.

• Lucintel forecasts that, within the drug type category, agonists will remain the larger segment over the forecast period due to the growing aging population and increase in the prevalence of opioid abuse.
• Within the distribution channel category, hospital pharmacies will remain the larger segment due to rising expenditure by the government to develop healthcare infrastructure.
• In terms of regions, North America will remain the largest region over the forecast period due to a rise in the number of product launches and product approval for opioid use disorder.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Opioid Use Disorder (OUD) Market

Emerging trends in the opioid use disorder (OUD) market are shaping the future of treatment with advancements in medication, technology, and holistic approaches. These trends reflect a shift towards more comprehensive and personalized care strategies.

• Increased Use of Digital Health Technologies: Digital health technologies

s, including telemedicine and mobile health apps, are being increasingly integrated into OUD treatment plans. These tools provide remote monitoring, virtual counseling, and personalized treatment adjustments, improving patient engagement and access to care.

• Advancements in Medication-Assisted Treatment (MAT): There have been significant innovations in MAT, including extended-release formulations and novel combination therapies. These advancements enhance treatment adherence and reduce the potential for misuse, offering more effective and long-lasting solutions for managing OUD.
• Focus on Integrated Care Models: Integrated care models that combine OUD treatment with mental health and social support services are gaining traction. This holistic approach addresses the multifaceted needs of patients, improving overall outcomes and reducing the risk of relapse.
• Expansion of Harm Reduction Programs: Harm reduction strategies, such as needle exchange programs and supervised consumption sites, are being expanded. These programs aim to reduce the negative health consequences of drug use and provide pathways to treatment and recovery.
• Emphasis on Personalized Medicine: Personalized medicine approaches, including genetic testing and individualized treatment plans, are becoming more prevalent. These strategies tailor treatment to the specific needs and characteristics of each patient, improving efficacy and minimizing side effects.

These emerging trends are reshaping the OUD market by introducing more effective, personalized, and integrated approaches to treatment. The focus on digital health, advanced medications, and holistic care models reflects a shift towards improving patient outcomes and addressing the complex needs of those affected by opioid use disorder.

Recent Developments in the Opioid Use Disorder (OUD) Market

Recent developments in the opioid use disorder (OUD) market have focused on improving treatment options, expanding access, and enhancing support systems. These changes are driven by the ongoing need to address the opioid crisis and provide effective, comprehensive care.

• Expansion of Medication-Assisted Treatment (MAT): New MAT formulations and extended-release options have been introduced, improving treatment adherence and efficacy. Innovations in buprenorphine and naltrexone formulations offer better management of withdrawal symptoms and relapse prevention.
• Integration of Digital Tools: The adoption of digital health tools, including telemedicine platforms and mobile apps, has enhanced the delivery of OUD treatment. These tools facilitate remote monitoring, virtual counseling, and data-driven adjustments to treatment plans.
• Strengthening Harm Reduction Initiatives: Governments and organizations have increased funding and support for harm reduction programs. Needle exchange programs, supervised consumption sites, and naloxone distribution efforts are expanding, aiming to reduce the negative impact of opioid use.
• Policy and Regulatory Changes: New regulations and policies have been implemented to improve access to OUD treatments and support services. Policies include expanded insurance coverage for MAT and initiatives to reduce stigma and increase public awareness.
• Focus on Integrated Care Models: Integrated care models that combine OUD treatment with mental health and social support services are being promoted. These models address the comprehensive needs of patients and enhance overall treatment effectiveness.

These recent developments reflect a concerted effort to improve OUD treatment and support systems. By focusing on medication advancements, digital tools, harm reduction, policy changes, and integrated care, the market is evolving to better address the complexities of opioid use disorder and support patient recovery.

Strategic Growth Opportunities for Opioid Use Disorder (OUD) Market

The opioid use disorder (OUD) market presents several strategic growth opportunities across various applications. Leveraging these opportunities can enhance treatment outcomes, expand access, and address the ongoing opioid crisis effectively.

• Expansion of MAT Programs: Expanding medication-assisted treatment programs to underserved areas offers significant growth potential. Increasing the availability of MAT options, such as buprenorphine and methadone, can improve access to effective treatment for those struggling with OUD.
• Integration of Digital Health Solutions: The incorporation of digital health solutions, including telemedicine and mobile apps, provides growth opportunities. These tools enhance treatment delivery, patient engagement, and monitoring, creating new avenues for market expansion.
• Development of Novel Therapies: Investing in research and development of novel therapies, such as new drug formulations and combination treatments, presents growth opportunities. Innovative therapies that address unmet needs can capture market share and offer improved treatment options.
• Expansion of Harm Reduction Programs: Expanding harm reduction programs, such as needle exchange services and supervised consumption sites, offers growth opportunities. These programs can reduce the impact of opioid use and provide pathways to treatment and recovery.
• Enhancement of Integrated Care Models: Developing and implementing integrated care models that combine OUD treatment with mental health and social support services presents growth potential. These models improve patient outcomes and address the multifaceted needs of individuals with OUD.

Strategic growth opportunities in the OUD market include expanding MAT programs, integrating digital health solutions, developing novel therapies, scaling harm reduction initiatives, and enhancing integrated care models. These opportunities align with the evolving needs of the market and can drive significant improvements in treatment and recovery outcomes.

Opioid Use Disorder (OUD) Market Driver and Challenges

The opioid use disorder (OUD) market is significantly influenced by various drivers and challenges that encompass technological advancements, economic factors, and regulatory changes. The drivers include innovations in treatment options, increased awareness, policy reforms, economic incentives, and improved access to care. Challenges, on the other hand, involve regulatory hurdles, economic barriers, and issues related to treatment adherence and accessibility. Understanding these factors is crucial for stakeholders aiming to navigate the complexities of the OUD market and enhance strategies for effective treatment and management.

The factors responsible for driving the opioid use disorder (OUD) market include:

1. Technological Advancements: Innovations in treatment technologies, such as digital health tools and advanced medication formulations, are driving growth in the OUD market. Digital platforms facilitate remote monitoring, telemedicine, and personalized treatment plans, improving patient engagement and outcomes. New drug formulations, including extended-release options, enhance the efficacy and convenience of treatment, contributing to increased market demand.

2. Increased Awareness and Education: Growing awareness about the opioid crisis and OUD has led to increased demand for effective treatments. Educational campaigns and public health initiatives are improving understanding of opioid addiction, reducing stigma, and encouraging individuals to seek treatment. This heightened awareness is driving market growth as more people recognize the need for OUD management solutions.

3. Policy and Regulatory Reforms: Changes in policies and regulations are facilitating better access to OUD treatments. Government initiatives, such as expanded insurance coverage for medication-assisted treatment (MAT) and supportive legislation, are reducing barriers to care. These reforms are encouraging healthcare providers to offer a wider range of treatment options and improving overall access for patients.

4. Economic Incentives and Funding: Increased funding from government and private sources is supporting OUD treatment programs and research. Economic incentives, such as subsidies for MAT and grants for addiction treatment facilities, are making it easier for providers to offer comprehensive care. This financial support is driving market growth by enhancing treatment availability and innovation.

5. Expansion of Treatment Access: Efforts to expand access to OUD treatments, particularly in underserved and rural areas, are driving market growth. Initiatives to increase the number of treatment centers, provide mobile treatment units, and integrate care into primary health services are improving accessibility. These efforts are ensuring that more individuals can receive the necessary care for managing OUD.

Challenges in the opioid use disorder (OUD) market include:

1. Regulatory Hurdles: Navigating complex regulatory requirements and obtaining approvals for new treatments can be challenging. Variability in regulations across regions can delay market entry for innovative therapies and create barriers to widespread adoption. Compliance with stringent guidelines can also increase costs for manufacturers and limit treatment availability.

2. Economic Barriers: High costs associated with OUD treatments, including medications and therapy programs, can be a significant barrier. Economic constraints may limit patient access to necessary care and affect treatment adherence. Insufficient insurance coverage and out-of-pocket expenses can further exacerbate these challenges, impacting overall market growth.

3. Treatment Adherence and Accessibility Issues: Ensuring consistent treatment adherence and addressing accessibility issues pose significant challenges. Patients may struggle with adherence due to side effects, stigma, or lack of support. Limited availability of treatment centers, particularly in remote areas, can also hinder access and affect the effectiveness of OUD management efforts.

The opioid use disorder market is shaped by a complex interplay of drivers and challenges. Technological advancements, increased awareness, policy reforms, economic incentives, and expanded access are key drivers that enhance treatment effectiveness and availability. However, regulatory hurdles, economic barriers, and issues with treatment adherence and accessibility present significant challenges. Addressing these factors is crucial for optimizing market strategies and improving outcomes for individuals affected by opioid use disorder. Understanding and navigating these dynamics will be essential for stakeholders seeking to advance the OUD treatment landscape.

List of Opioid Use Disorder (OUD) Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies opioid use disorder (OUD) companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the opioid use disorder (OUD) companies profiled in this report include-

• Hikma Pharmaceuticals
• Indivior
• Titan Pharmaceuticals
• Reckitt Benckiser Pharmaceuticals
• Camurus
• BioDelivery Sciences International
• Sandoz

Opioid Use Disorder (OUD) by Segment

The study includes a forecast for the global opioid use disorder (OUD) by drug type, age group, route of administration, distribution channel, and region.

Opioid Use Disorder (OUD) Market by Drug Type [Analysis by Value from 2018 to 2030]:

• Agonist
• Antagonist

Opioid Use Disorder (OUD) Market by Age Group [Analysis by Value from 2018 to 2030]:

• 19 To 39
• 40 To 59
• Age 60 and Over

List of Opioid Use Disorder (OUD) Companies

Opioid Use Disorder (OUD) Market by Route of Administration [Analysis by Value from 2018 to 2030]:

• Oral
• Intravenous
• Sublingual

Opioid Use Disorder (OUD) Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific

Opioid Use Disorder (OUD) Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacy
• Retail Pharmacy

Country Wise Outlook for the Opioid Use Disorder (OUD) Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below is a summary of recent developments by major opioid use disorder producers in key regions: the USA, China, India, Japan, and Germany.

• United States: In the US, there has been a notable increase in the availability of naloxone and buprenorphine, with expanded access through recent legislation. The FDA approved new formulations of buprenorphine for enhanced efficacy and ease of use. Additionally, federal and state governments are implementing comprehensive strategies, including expanded treatment facilities and harm reduction programs.
• China: China has been focusing on improving access to opioid dependence treatments, including methadone maintenance therapy (MMT) and buprenorphine. Recent policy changes have aimed to integrate OUD treatment into broader healthcare services. Efforts to increase public awareness and reduce stigma around addiction are also being emphasized.
• Germany: Germany has advanced its treatment protocols with new guidelines incorporating both pharmacological and psychosocial interventions. The integration of digital health solutions, such as telemedicine for therapy management, has been a key development. Increased funding for addiction treatment services has also been noted.
• India: In India, there is a growing focus on increasing access to OUD treatments, with an emphasis on expanding methadone and buprenorphine programs. Recent developments include the establishment of more treatment centers and community-based programs. Public awareness campaigns are being strengthened to combat stigma and promote treatment options.
• Japan: Japan has introduced new regulations to improve access to opioid treatment programs. There has been an increase in the availability of treatment options such as buprenorphine and extended-release naltrexone. Additionally, efforts to enhance coordination between healthcare providers and support systems have been a focus.

Features of the Global Opioid Use Disorder (OUD) Market

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the opioid use disorder (OUD) market by drug type (agonist and antagonist), age group (19 to 39, 40 to 59, and age 60 and over), route of administration (oral, intravenous, and sublingual), distribution channel (hospital pharmacy and retail pharmacy), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Opioid Use Disorder (OUD) Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Opioid Use Disorder (OUD) Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Opioid Use Disorder (OUD) Market by Drug Type
  • 3.3.1: Agonist
  • 3.3.2: Antagonist
• 3.4: Global Opioid Use Disorder (OUD) Market by Age Group
  • 3.4.1: 19 to 39
  • 3.4.2: 40 to 59
  • 3.4.3: Age 60 and over
• 3.5: Global Opioid Use Disorder (OUD) Market by Route of Administration
  • 3.5.1: Oral
  • 3.5.2: Intravenous
  • 3.5.3: Sublingual
• 3.6: Global Opioid Use Disorder (OUD) Market by Distribution Channel
  • 3.6.1: Hospital pharmacy
  • 3.6.2: Retail Pharmacy

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Opioid Use Disorder (OUD) Market by Region
• 4.2: North American Opioid Use Disorder (OUD) Market
  • 4.2.1: North American Market by Drug Type: Agonist and Antagonist
  • 4.2.2: North American Market by Distribution Channel: Hospital pharmacy and Retail Pharmacy
• 4.3: European Opioid Use Disorder (OUD) Market
  • 4.3.1: European Market by Drug Type: Agonist and Antagonist
  • 4.3.2: European Market by Distribution Channel: Hospital pharmacy and Retail Pharmacy
• 4.4: APAC Opioid Use Disorder (OUD) Market
  • 4.4.1: APAC Market by Drug Type: Agonist and Antagonist
  • 4.4.2: APAC Market by Distribution Channel: Hospital pharmacy and Retail Pharmacy
• 4.5: ROW Opioid Use Disorder (OUD) Market
  • 4.5.1: ROW Market by Drug Type: Agonist and Antagonist
  • 4.5.2: ROW Market by Distribution Channel: Hospital pharmacy and Retail Pharmacy

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Opioid Use Disorder (OUD) Market by Drug Type
  • 6.1.2: Growth Opportunities for the Global Opioid Use Disorder (OUD) Market by Age Group
  • 6.1.3: Growth Opportunities for the Global Opioid Use Disorder (OUD) Market by Route of Administration
  • 6.1.4: Growth Opportunities for the Global Opioid Use Disorder (OUD) Market by Distribution Channel
  • 6.1.5: Growth Opportunities for the Global Opioid Use Disorder (OUD) Market by Region
• 6.2: Emerging Trends in the Global Opioid Use Disorder (OUD) Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Opioid Use Disorder (OUD) Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Opioid Use Disorder (OUD) Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Hikma Pharmaceuticals
• 7.2: Indivior
• 7.3: Titan Pharmaceuticals
• 7.4: Reckitt Benckiser Pharmaceuticals
• 7.5: Camurus
• 7.6: BioDelivery Sciences International
• 7.7: Sandoz